BiotechTube
Home/GeneVentiv Therapeutics/Paris Margaritis
PM

Paris Margaritis

CSO

GeneVentiv Therapeutics

Therapeutic Areas

Rare Genetic DiseasesHematologyMetabolic Disorders

GeneVentiv Therapeutics Pipeline

DrugIndicationPhase
GENV-HEMHemophilia (including patients with inhibitors)Pre-clinical
GENV-002Pompe Disease (Infantile-Onset and Late-Onset)Pre-clinical

Leadership Team at GeneVentiv Therapeutics

DR
Damon R. Race
CEO
CL
Chengwen Li
Co-Founder, Scientific Advisor
View full GeneVentiv Therapeutics profile